1
|
Rocha-Filho CR, Ramalho GS, Martins JWL, Lucchetta RC, Pinto ACPN, da Rocha AP, Trevisani GFM, Reis FSDA, Ferla LJ, Mastroianni PDC, Correa L, Saconato H, Trevisani VFM. Economic burden of respiratory syncytial and parainfluenza viruses in children of upper-middle-income countries: a systematic review. J Pediatr (Rio J) 2023; 99:537-545. [PMID: 37247828 PMCID: PMC10594008 DOI: 10.1016/j.jped.2023.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 05/10/2023] [Accepted: 05/15/2023] [Indexed: 05/31/2023] Open
Abstract
OBJECTIVE To identify and assess the current evidence available about the costs of managing hospitalized pediatric patients diagnosed with Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in upper-middle-income countries. METHODS The authors conducted a systematic review across seven key databases from database inception to July 2022. Costs extracted were converted into 2022 International Dollars using the Purchasing Power Parity-adjusted. PROSPERO identifier: CRD42020225757. RESULTS No eligible study for PIV3 was recovered. For RSV, cost analysis and COI studies were performed for populations in Colombia, China, Malaysia, and Mexico. Comparing the total economic impact, the lowest cost per patient at the pediatric ward was observed in Malaysia ($ 347.60), while the highest was in Colombia ($ 709.66). On the other hand, at pediatric ICU, the lowest cost was observed in China ($ 1068.26), while the highest was in Mexico ($ 3815.56). Although there is no consensus on the major cost driver, all included studies described that the medications (treatment) consumed over 30% of the total cost. A high rate of inappropriate prescription drugs was observed. CONCLUSION The present study highlighted how RSV infection represents a substantial economic burden to health care systems and to society. The findings of the included studies suggest a possible association between baseline risk status and expenditures. Moreover, it was observed that an important amount of the cost is destinated to treatments that have no evidence or support in most clinical practice guidelines.
Collapse
Affiliation(s)
- César Ramos Rocha-Filho
- Universidade Federal de São Paulo, Escola Paulista de Medicina, Programa de Pós-Graduação em Saúde Baseada em Evidências, São Paulo, SP, Brazil
| | - Gabriel Sodré Ramalho
- Universidade Federal de São Paulo, Escola Paulista de Medicina, Graduação em Medicina, São Paulo, SP, Brazil
| | - Johnny Wallef Leite Martins
- Universidade Estadual de São Paulo, Escola de Ciências Farmacêuticas, Programa de Pós-Graduação em Ciências Farmacêuticas, Araraquara, SP, Brazil
| | - Rosa Camila Lucchetta
- Universidade Estadual de São Paulo, Escola de Ciências Farmacêuticas, Departamento de Fármacos e Medicamentos, Araraquara, SP, Brazil; Hospital Alemão Oswaldo Cruz, Departamento de Sustentabilidade e Responsabilidade Social, São Paulo, SP, Brazil
| | - Ana Carolina Pereira Nunes Pinto
- Universidade Federal de São Paulo, Escola Paulista de Medicina, Programa de Pós-Graduação em Saúde Baseada em Evidências, São Paulo, SP, Brazil; Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau, Barcelona, Spain; Universidade Federal do Amapá, Departamento de Ciências Biológicas e da Saúde, Macapá, AP, Brazil
| | - Aline Pereira da Rocha
- Universidade Federal de São Paulo, Escola Paulista de Medicina, Programa de Pós-Graduação em Saúde Baseada em Evidências, São Paulo, SP, Brazil
| | | | | | - Laura Jantsch Ferla
- Universidade Federal de São Paulo, Escola Paulista de Medicina, Graduação em Medicina, São Paulo, SP, Brazil
| | - Patrícia de Carvalho Mastroianni
- Universidade Estadual de São Paulo, Escola de Ciências Farmacêuticas, Programa de Pós-Graduação em Ciências Farmacêuticas, Araraquara, SP, Brazil; Universidade Estadual de São Paulo, Escola de Ciências Farmacêuticas, Departamento de Fármacos e Medicamentos, Araraquara, SP, Brazil
| | - Luci Correa
- Universidade Federal de São Paulo, Escola Paulista de Medicina, Disciplina de Infectologia, São Paulo, SP, Brazil
| | - Humberto Saconato
- Universidade Federal de São Paulo, Escola Paulista de Medicina, Disciplina de Emergência e Medicina Baseada em Evidências, São Paulo, SP, Brazil.
| | - Virgínia Fernandes Moça Trevisani
- Universidade Federal de São Paulo, Escola Paulista de Medicina, Programa de Pós-Graduação em Saúde Baseada em Evidências, São Paulo, SP, Brazil; Universidade de Santo Amaro, Faculdade de Medicina, São Paulo, SP, Brazil; Universidade Federal de São Paulo, Escola Paulista de Medicina, Disciplina de Emergência e Medicina Baseada em Evidências, São Paulo, SP, Brazil
| |
Collapse
|
2
|
Field E, Strathearn M, Boyd-Skinner C, Dyda A. Usefulness of linked data for infectious disease events: a systematic review. Epidemiol Infect 2023; 151:e46. [PMID: 36843485 PMCID: PMC10052405 DOI: 10.1017/s0950268823000316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2023] Open
Abstract
Surveillance is a key public health function to enable early detection of infectious disease events and inform public health action. Data linkage may improve the depth of data for response to infectious disease events. This study aimed to describe the uses of linked data for infectious disease events. A systematic review was conducted using Pubmed, CINAHL and Web of Science. Studies were included if they used data linkage for an acute infectious disease event (e.g. outbreak of disease). We summarised the event, study aims and designs; data sets; linkage methods; outcomes reported; and benefits and limitations. Fifty-four studies were included. Uses of linkage for infectious disease events included assessment of severity of disease and risk factors; improved case finding and contact tracing; and vaccine uptake, safety and effectiveness. The ability to conduct larger scale population level studies was identified as a benefit, in particular for rarer exposures, risk factors or outcomes. Limitations included timeliness, data quality and inability to collect additional variables. This review demonstrated multiple uses of data linkage for infectious disease events. As infectious disease events occur without warning, there is a need to establish pre-approved protocols and the infrastructure for data-linkage to enhance information available during an event.
Collapse
Affiliation(s)
- Emma Field
- National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia
- Menzies School of Health Research, Charles Darwin University, Darwin, Australia
| | - Melanie Strathearn
- School of Population Health, University of Queensland, Brisbane, Australia
| | | | - Amalie Dyda
- School of Population Health, University of Queensland, Brisbane, Australia
| |
Collapse
|
3
|
Greiff DRL, Patterson-Robert A, Blyth CC, Glass K, Moore HC. Epidemiology and seasonality of human parainfluenza serotypes 1-3 in Australian children. Influenza Other Respir Viruses 2021; 15:661-669. [PMID: 33491337 PMCID: PMC8404051 DOI: 10.1111/irv.12838] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Accepted: 01/03/2021] [Indexed: 01/03/2023] Open
Abstract
Background Parainfluenza viruses are significant contributors to childhood respiratory illness worldwide, although detailed epidemiological studies are lacking. Few recent Australian studies have investigated serotype‐specific PIV epidemiology, and there is a paucity of southern hemisphere PIV reports. We report age‐stratified PIV hospitalisation rates and a mathematical model of PIV seasonality and dynamics in Western Australia (WA). Methods We used linked perinatal, hospital admission and laboratory diagnostic data of 469 589 children born in WA between 1996 and 2012. Age‐specific rates of viral testing and PIV detection in hospitalised children were determined using person time‐at‐risk analysis. PIV seasonality was modelled using a compartmental SEIRS model and complex demodulation methods. Results From 2000 to 2012, 9% (n = 43 627) of hospitalised children underwent PIV testing, of which 5% (n = 2218) were positive for PIV‐1, 2 or 3. The highest incidence was in children aged 1‐5 months (PIV‐1:62.6 per 100 000 child‐years, PIV‐2:26.3/100 000, PIV‐3:256/100 000), and hospitalisation rates were three times higher for Aboriginal children compared with non‐Aboriginal children overall (IRR: 2.93). PIV‐1 peaked in the autumn of even‐numbered years, and PIV‐3 annually in the spring, whereas PIV‐2 had inconsistent peak timing. Fitting models to the higher incidence serotypes estimated reproduction numbers of 1.24 (PIV‐1) and 1.72 (PIV‐3). Conclusion PIV‐1 and 3 are significant contributors towards infant respiratory hospitalisations. Interventions should prioritise children in the first 6 months of life, with respect to the observed autumn PIV‐1 and spring PIV‐3 activity peaks. Continued surveillance of all serotypes and investigation into PIV‐1 and 3 interventions should be prioritised.
Collapse
Affiliation(s)
- Daniel R L Greiff
- Wesfarmers Centre for Vaccine and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia
| | - Alice Patterson-Robert
- Medical School, College of Health and Medicine, Australian National University, Canberra, ACT, Australia
| | - Christopher C Blyth
- Wesfarmers Centre for Vaccine and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.,School of Medicine, University of Western Australia, Perth, WA, Australia.,Department of Infectious Diseases, Perth Children's Hospital, Perth, WA, Australia.,Department of Microbiology, PathWest Laboratory Medicine, Perth, WA, Australia
| | - Kathryn Glass
- Research School of Population Health, Australian National University, Canberra, ACT, Australia
| | - Hannah C Moore
- Wesfarmers Centre for Vaccine and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia
| |
Collapse
|